Wegovy Tablets Vs Injections

If you have been researching weight loss medication in the UK, there is a very good chance you have come across the name Wegovy. It has been talked about extensively in the media, prescribed by NHS clinicians, and recommended by weight management specialists across the country. But one question keeps coming up in online searches and pharmacy consultations: do Wegovy tablets actually exist, or is Wegovy only available as an injection? This blog cuts through the confusion, explains exactly what forms semaglutide comes in, and helps you understand which weight management option is right for your situation in 2026.

Quick Summary

Wegovy is a brand name for semaglutide, a GLP-1 receptor agonist approved in the UK for chronic weight management. While the Wegovy brand itself is only licensed as a subcutaneous injection, oral semaglutide does exist under a different brand name, and understanding the difference is important before you make any decisions about treatment.

• Wegovy is currently only available as a once-weekly subcutaneous injection in the UK
• Oral semaglutide (Rybelsus) exists but is licensed for type 2 diabetes, not weight loss
• The active ingredient, semaglutide, is the same in both products but the dose and indication differ
• Alternatives such as Mounjaro (tirzepatide) weight loss injections are also available for eligible patients
• A prescription assessment from a qualified UK prescriber is required before starting any semaglutide-based treatment

Table of Contents

• What Is Wegovy and How Does Semaglutide Work?
• Do Wegovy Tablets Actually Exist? The Full Explanation
• Comparing Wegovy to Other UK-Approved Weight Loss Treatments
• Who Qualifies for Semaglutide Weight Loss Treatment in the UK?
• Common Side Effects and How to Manage Them
• Understanding the Wegovy Dose Escalation Schedule
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• FAQs

What Is Wegovy and How Does Semaglutide Work?

Wegovy is the brand name for semaglutide at a higher dose formulation, developed specifically for chronic weight management in adults. It was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK and has since become one of the most widely discussed prescription treatments for obesity. The active ingredient, semaglutide, belongs to a class of medicines called GLP-1 receptor agonists, which mimic a naturally occurring gut hormone called glucagon-like peptide-1.

When semaglutide is introduced into the body, it binds to GLP-1 receptors in the brain, the pancreas, and the gastrointestinal tract. This triggers several effects that work together to reduce appetite and lower caloric intake. You feel full more quickly when eating, your stomach empties more slowly, and the reward signals associated with food cravings are dampened. For people who have struggled with hunger-driven overeating for years, this is a genuinely significant clinical intervention — not a quick fix, but a pharmacological support tool that addresses the biological drivers of weight gain.

Wegovy is not a lifestyle product or supplement. It is a prescription-only medicine, which means it must be assessed and approved by a qualified clinician before you can access it. In the UK, this can be done through the NHS or through regulated private online pharmacies and prescribing services. Semaglutide was first used in a lower dose for type 2 diabetes management (under the brand name Ozempic), before being studied and approved at a higher dose for weight management under the Wegovy brand. By 2026, it remains one of the most studied and clinically validated weight loss treatments available in the UK.

• GLP-1 receptor agonists mimic a natural gut hormone
• Semaglutide slows gastric emptying and reduces appetite signals in the brain
• Wegovy is a prescription-only medicine — it cannot be purchased over the counter
• The same active ingredient is used in diabetes treatment (Ozempic) at a lower dose
• Clinical trials showed average body weight reductions of 14–15% over 68 weeks

Do Wegovy Tablets Actually Exist? The Full Explanation

This is probably the most searched question around this medication, and the answer requires a little nuance. The Wegovy brand itself does not come in a tablet form. Wegovy is exclusively available as a pre-filled injection pen, designed for subcutaneous (under the skin) self-administration once a week. The injection is typically administered into the stomach, thigh, or upper arm. For many people, the idea of a weekly injection is an initial concern — but in practice, the needles are extremely fine, and the process becomes routine within a few weeks.

However, oral semaglutide does exist. The tablet form is called Rybelsus and is manufactured by the same company, Novo Nordisk. Rybelsus contains the same active ingredient — semaglutide — but it is licensed exclusively for the management of type 2 diabetes in adults, not for weight loss. The doses used in Rybelsus (3mg, 7mg, and 14mg) are considerably lower than those used in Wegovy for weight management (which reaches a maintenance dose of 2.4mg weekly by injection — a dose that achieves much higher systemic bioavailability than an oral equivalent). This is a crucial distinction that is often misunderstood when people search for Wegovy tablets online.

There is ongoing pharmaceutical research into higher-dose oral semaglutide for weight management, and some clinical trials are exploring this route. But as of 2026, no oral version of semaglutide at Wegovy-equivalent doses is licensed in the UK for weight loss. If you come across websites claiming to sell Wegovy tablets for weight loss, exercise extreme caution — these products are either mislabelled, unlicensed, or potentially counterfeit.

• Wegovy is only available as a subcutaneous injection pen in the UK
• Rybelsus is oral semaglutide but licensed only for type 2 diabetes
• Oral semaglutide for weight loss is not yet MHRA-licensed as of 2026
• Claims of Wegovy tablets for weight loss online should be treated with extreme caution
• Always purchase prescription weight loss treatments from a GPhC-registered pharmacy

Comparing Wegovy to Other UK-Approved Weight Loss Treatments

Wegovy is not the only game in town when it comes to prescription weight loss treatment in the UK. Understanding where it sits relative to other options helps you have an informed conversation with your prescriber and make the right choice for your health goals and lifestyle. The main prescription alternatives currently available include tirzepatide (Mounjaro), liraglutide (Saxenda), and orlistat.

Tirzepatide, sold under the brand name Mounjaro, works on both GLP-1 and GIP receptors, making it a dual agonist. Clinical trial data suggests tirzepatide may produce greater average weight loss than semaglutide in head-to-head comparisons. It is also administered as a weekly subcutaneous injection. Liraglutide (Saxenda) is an older GLP-1 agonist that requires a daily injection rather than a weekly one, which many patients find less convenient. Orlistat, available over the counter as Orlos (orlistat) 60mg weight loss aid, works through an entirely different mechanism — it inhibits the absorption of dietary fat in the gut rather than acting on appetite hormones.

For those who are not yet ready for a prescription injection, over-the-counter options such as XLS Medical Weight Loss Plus tablets and XLS Medical Direct Fat Binder sachets can provide supplementary support alongside dietary changes, though their effects are considerably more modest than prescription GLP-1 treatments.

Treatment	Active Ingredient	Form	Frequency	Avg. Weight Loss	Prescription Required
Wegovy	Semaglutide 2.4mg	Subcutaneous injection	Once weekly	~15% body weight	Yes
Mounjaro	Tirzepatide	Subcutaneous injection	Once weekly	~20% body weight	Yes
Saxenda	Liraglutide 3mg	Subcutaneous injection	Once daily	~8% body weight	Yes
Orlos (Orlistat)	Orlistat 60mg	Oral capsule	Three times daily	~5–7% body weight	No (OTC at 60mg)
XLS Medical	Litramine (fibre complex)	Tablet/sachet	Three times daily	Modest / variable	No
Rybelsus	Semaglutide 3–14mg	Oral tablet	Once daily	Varies (diabetes use)	Yes (diabetes only)

Who Qualifies for Semaglutide Weight Loss Treatment in the UK?

Not everyone who wants to lose weight will qualify for Wegovy on the NHS or through private prescription. NICE (the National Institute for Health and Care Excellence) has published specific guidance on who is eligible for semaglutide-based treatment. Broadly speaking, you need to have a body mass index (BMI) of 30 or above (or 27.5 or above if you are from a South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean background, where health risks arise at lower BMI thresholds). You also need to have at least one weight-related health condition, such as type 2 diabetes, hypertension, sleep apnoea, or cardiovascular disease.

On the NHS, access is primarily managed through specialist weight management services, and availability can vary by region. For many people, private prescription routes are a faster and more accessible option. Through a regulated online pharmacy or prescribing service, you complete a clinical consultation — usually a detailed online questionnaire reviewed by a qualified prescriber — to determine your suitability. The prescriber will check your current medications, medical history, and any contraindications before approving your prescription.

There are also important contraindications to be aware of. Semaglutide should not be used by people with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or those with multiple endocrine neoplasia syndrome type 2 (MEN2). It is not suitable during pregnancy or breastfeeding, and caution is advised in people with a history of pancreatitis. A thyroid function test may be recommended as part of your pre-treatment assessment if there are any relevant concerns about your thyroid health.

• BMI of 30+ (or 27.5+ with weight-related health conditions) generally required
• At least one comorbidity such as hypertension, type 2 diabetes, or sleep apnoea strengthens eligibility
• History of medullary thyroid cancer or MEN2 is a contraindication
• Not suitable during pregnancy, breastfeeding, or for those with active pancreatitis
• A clinical consultation is mandatory — never attempt to access treatment without one

Common Side Effects and How to Manage Them

One of the most common reasons people research Wegovy before starting treatment is concern about side effects. The good news is that for most people, the side effects are manageable and tend to be most pronounced during the initial dose escalation phase. The most frequently reported side effects are gastrointestinal in nature: nausea, vomiting, diarrhoea, constipation, and stomach discomfort. These occur because the medication slows gastric emptying — the same mechanism that makes you feel full — and the gut takes time to adjust.

Nausea is the most widely reported issue, affecting a significant proportion of users in the early weeks of treatment. To minimise this, clinicians generally recommend eating smaller meals, avoiding high-fat and spicy foods, staying well hydrated, and not lying down immediately after eating. In most cases, nausea improves considerably after the first few weeks as the body adapts to each dose level. Some people also experience headaches during the adjustment period, and occasionally there are reports of fatigue or dizziness, particularly around the time of injection.

More serious but less common side effects include pancreatitis, gallbladder problems, and changes in heart rate. These require prompt medical assessment if they occur. If you experience severe abdominal pain that radiates to the back, persistent vomiting, or palpitations, you should seek medical advice promptly. It is also worth being aware that Wegovy may affect the absorption of other oral medications due to its effect on gastric emptying, so always inform your prescriber of everything you take, including Formolite L112 weight management tablets or any other supplements.

• Nausea is the most common side effect, usually worst in the first few weeks
• Small, frequent, low-fat meals can significantly reduce gastrointestinal discomfort
• Staying hydrated is particularly important if experiencing vomiting or diarrhoea
• Severe abdominal pain, jaundice, or palpitations warrant immediate medical review
• Side effects typically reduce as the body adapts at each new dose level

Understanding the Wegovy Dose Escalation Schedule

The Wegovy dose escalation schedule is specifically designed to minimise side effects by introducing semaglutide gradually into the system. The starting dose is 0.25mg once weekly for the first four weeks. This is too low to produce significant weight loss on its own, but it allows the body to begin adjusting to the medication before the dose is increased. Understanding this from the outset helps manage expectations — you are unlikely to see dramatic results in the first month, and that is perfectly normal.

After four weeks at 0.25mg, the dose increases to 0.5mg weekly, and then continues to step up every four weeks: to 1mg, then 1.7mg, and finally to the maintenance dose of 2.4mg weekly. The entire escalation process takes approximately 16 to 20 weeks. Most of the clinically meaningful weight loss occurs after the maintenance dose of 2.4mg has been established, with maximum weight reduction typically observed between the 52nd and 68th week of treatment according to the STEP clinical trial programme. If you find a particular dose step causes significant side effects, your prescriber may recommend staying at that dose for longer before escalating further.

It is also important to understand what happens if you miss a dose. If you miss an injection and your next scheduled dose is more than two days away, you should take the missed dose as soon as possible. If the next scheduled dose is within two days, skip the missed one and resume your normal schedule. Never double up doses. Consistency matters enormously in this treatment — erratic dosing is one of the most common reasons people do not achieve the outcomes seen in clinical trials. For those managing nausea alongside this journey, products such as Alka-Seltzer Original effervescent tablets may offer some relief from mild stomach discomfort, though always check with your prescriber before adding anything new.

• Starting dose is 0.25mg weekly — this is a titration dose, not a therapeutic dose
• Dose increases every four weeks until reaching 2.4mg weekly maintenance dose
• Full escalation takes approximately 16–20 weeks
• Maximum weight loss typically seen between weeks 52 and 68
• Missing doses should be managed carefully — never double up on injections
• Your prescriber may slow the escalation if side effects are problematic

Key Takeaways

• Wegovy is a once-weekly subcutaneous injection, not a tablet — no MHRA-licensed tablet version for weight loss currently exists in the UK
• Oral semaglutide (Rybelsus) is a real product but is only licensed for type 2 diabetes management, not weight loss
• Semaglutide works by mimicking the GLP-1 gut hormone to reduce appetite, slow gastric emptying, and support sustained weight loss
• Eligibility requires a BMI of 30+ (or 27.5+ in certain ethnic groups) plus at least one weight-related comorbidity, assessed by a qualified UK prescriber
• The dose escalation schedule is gradual by design — patience and consistency are key to achieving the 15% average weight reduction seen in clinical trials

When to Seek Professional Advice

There are several situations where you should seek professional medical advice promptly rather than attempting to manage things independently. If you experience severe or persistent abdominal pain, particularly pain that radiates to your back and is accompanied by nausea or vomiting, this could indicate pancreatitis and requires urgent assessment. Similarly, yellowing of the skin or whites of the eyes (jaundice), clay-coloured stools, or severe upper abdominal pain may suggest gallbladder problems.

You should also seek advice if you notice a lump or swelling in your neck, experience hoarseness, or have difficulty swallowing — these symptoms should be investigated to rule out any thyroid-related concerns. If you are experiencing side effects so severe that you cannot maintain adequate nutrition or hydration, this also warrants a conversation with your prescriber or GP.

More broadly, if you have been using Wegovy for three to four months at the maintenance dose and have not achieved at least 5% body weight reduction, your prescriber should review your treatment. Continuing treatment without meaningful benefit is not clinically justified, and there may be better-suited alternatives to explore. Speak to a qualified prescriber at Cured Pharmacy — our UK-based clinical team can review your case and guide you toward the most appropriate weight management option for your individual health profile.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal TA875. NICE, 2023.
2. Medicines and Healthcare products Regulatory Agency (MHRA). Wegovy (semaglutide) Summary of Product Characteristics. GOV.UK, updated 2024.
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The Lancet. STEP 1 Trial. 2021;396(10247):391–405.

Frequently Asked Questions

How long does it take to see results with semaglutide weight loss treatment?

How long it takes to see results with semaglutide depends on the individual, but most people begin to notice weight loss within the first four to eight weeks of treatment. Clinical trials show that significant weight reduction, often 10 to 15 percent of body weight, is typically achieved over 68 weeks at the maintenance dose.

Is Wegovy safe to use long term for weight management?

Wegovy is considered safe for long-term use in adults who meet the eligibility criteria, based on clinical trial data reviewed by the MHRA. Long-term safety studies running into 2026 continue to support its use, though regular monitoring by a prescriber is recommended to assess ongoing suitability and manage any side effects.

Can you take Wegovy with other weight loss supplements or medications?

Whether you can take Wegovy with other weight loss supplements or medications depends on what those products are. Wegovy should not be combined with other GLP-1 receptor agonists or insulin without medical supervision. Always inform your prescriber of every supplement and medicine you take before starting semaglutide treatment.

What is the dose of Wegovy for weight loss in the UK?

The dose of Wegovy for weight loss in the UK starts at 0.25mg once weekly for the first four weeks, then increases gradually every four weeks to reach the maintenance dose of 2.4mg once weekly. This stepped dose escalation is designed to reduce the likelihood of gastrointestinal side effects during treatment.